
Xbrane Biopharma Q2 2025 - Important months ahead

Redeye updates its view on Xbrane following its Q2 report. The BsUFA date at the end of October), which could open the US market for its ranibizumab biosimilar, marks an important potential catalyst for the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xbrane Biopharma Q2 2025 - Important months ahead